Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AU409 in Advanced Hepatocellular Carcinoma
NCT06374485Phase 1Completed
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- May 2024
- Primary completion
- Aug 2026
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AU-409 in hepatocellular carcinoma (HCC) (3 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started May 2024; status: completed.
02
Drugs
AU-409
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06374485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374485.